Mode
Text Size
Log in / Sign up
Phase 3 Completed N=366 Randomized Double-blind Treatment

A Study to Investigate the Antihypertensive Efficacy of MK0954

Source: ClinicalTrials.gov NCT00887250 ↗
Enrolled (actual)
366
Serious AEs
Results posted
Jun 2009
Primary outcomePrimary: Mean Change From Baseline in Trough Sitting Diastolic Blood Pressure (SiDBP) at Week 12 — -4.3; -7.9; -8.6 mm Hg

Summary

After a 4 week placebo period, patients were randomized to Placebo or Losartan 50 mg arms, after 6 weeks non-responders were up titrated to 100 mg losartan for the remaining 6 weeks. This study evaluated if losartan is more effective than placebo in lowering sitting diastolic blood pressure and is well tolerated in patients with mild to moderate hypertension.

Outcome Measures

OutcomeResultp-value
PRIMARY
Mean Change From Baseline in Trough Sitting Diastolic Blood Pressure (SiDBP) at Week 12
-4.3; -7.9; -8.6
SECONDARY
Categories of Hypertensive Response in Trough Diastolic Blood Pressure (SiDBP) at Week 6
14; 37; 37; 8; 20; 21
SECONDARY
Categories of Hypertensive Response in Trough Diastolic Blood Pressure (SiDBP) at Week 12
19; 40; 37; 12; 18; 24
SECONDARY
Mean Change From Baseline in Trough Sitting Diastolic Blood Pressure (SiDBP) at Week 6
-3.5; -6.9; -7.9
SECONDARY
Mean Change From Baseline in Peak Sitting Diastolic Blood Pressure (SiDBP) at Week 6
-4.1; -9.7; -8.9
SECONDARY
Mean Change From Baseline in Peak Sitting Diastolic Blood Pressure (SiDBP) at Week 12
-4.7; -9.5; -10.1

Eligibility Criteria

Inclusion Criteria

  • Patient has been diagnosed with mild to moderate hypertension (SDBP 95-115 mm Hg)
  • Patient has no medical problems or treatments that might effect their blood pressure

Exclusion Criteria

  • Pregnant or lactating females
  • Patient has secondary hypertension or malignant hypertension
  • Sitting systolic blood pressure > 210 mm Hg
  • History of stroke
  • History of myocardial infarction with in past year
  • Current or prior history of heart failure
  • Known hypersensitivity to losartan
  • Prior exposure to losartan
  • Patients known to be HIV positive
  • Patient is abusing or has abused alcohol or other drugs within the past 4 years
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00887250). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search